Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Intracerebroventricular Injections of Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild-Moderate Alzheimer's Disease
Sponsor: Regeneration Biomedical, Inc.
Summary
The goal of this Phase 2 clinical trial is to learn if repeated dosing of RB-ADSC (an investigational autologous cell product obtained from participant's own adipose tissue) enhances the positive preliminary results seen in Phase 1 for the of treatment for mild to moderate Alzheimer's Disease in adults. The clinical trial will also continue to evaluate the safety of repeated dosing of RB-ADSC. This study will primarily evaluate the effects of repeated dosing of RB-ADSC on cognitive performance compared to placebo control. Participants will receive RB-ADSC every 2 months for a total of 6 doses. Participants randomized into the placebo control group will have the option to cross over to receive treatment after completion of the primary phase of the study.
Official title: Phase 2a Assessment of Safety, Tolerability, and Efficacy of Repeated Dosing of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild to Moderate Alzheimer's Disease
Key Details
Gender
All
Age Range
45 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
115
Start Date
2025-11
Completion Date
2029-03
Last Updated
2025-10-03
Healthy Volunteers
No
Conditions
Interventions
RB-ADSC
RB-ADSC is an investigational an ex-vivo expanded autologous adipose-derived stem cell product
Placebo
0.9% NaCl USP